BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 32187665)

  • 41. TP53 mutations in endometrial cancers: relation to PTEN gene defects.
    Janiec-Jankowska A; Konopka B; Goluda C; Najmoła U
    Int J Gynecol Cancer; 2010 Feb; 20(2):196-202. PubMed ID: 20169661
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Molecular pathology of endometrial carcinoma: transcriptional signature in endometrioid tumors.
    Abal M; Planaguma J; Gil-Moreno A; Monge M; Gonzalez M; Baro T; Garcia A; Castellvi J; Ramon Y Cajal S; Xercavins J; Alameda F; Reventos J
    Histol Histopathol; 2006 Feb; 21(2):197-204. PubMed ID: 16329044
    [TBL] [Abstract][Full Text] [Related]  

  • 43. FGFR2 mutations are associated with poor outcomes in endometrioid endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study.
    Jeske YW; Ali S; Byron SA; Gao F; Mannel RS; Ghebre RG; DiSilvestro PA; Lele SB; Pearl ML; Schmidt AP; Lankes HA; Ramirez NC; Rasty G; Powell M; Goodfellow PJ; Pollock PM
    Gynecol Oncol; 2017 May; 145(2):366-373. PubMed ID: 28314589
    [TBL] [Abstract][Full Text] [Related]  

  • 44. PIK3CA and PTEN mutations in uterine endometrioid carcinoma and complex atypical hyperplasia.
    Hayes MP; Wang H; Espinal-Witter R; Douglas W; Solomon GJ; Baker SJ; Ellenson LH
    Clin Cancer Res; 2006 Oct; 12(20 Pt 1):5932-5. PubMed ID: 17062663
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Papillary proliferation of the endometrium: a clinicopathologic study of 59 cases of simple and complex papillae without cytologic atypia.
    Ip PP; Irving JA; McCluggage WG; Clement PB; Young RH
    Am J Surg Pathol; 2013 Feb; 37(2):167-77. PubMed ID: 23211295
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Localized Endometrial Proliferations of Pregnancy are Clonal Glandular Outgrowths Characterized by PTEN Loss and PIK3CA Pathogenic Variants.
    Wepy C; Chapel DB; Mutter GL; Quade BJ; Nucci MR; Parra-Herran C
    Mod Pathol; 2023 Aug; 36(8):100213. PubMed ID: 37172903
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Laminin C1 expression by uterine carcinoma cells is associated with tumor progression.
    Kashima H; Wu RC; Wang Y; Sinno AK; Miyamoto T; Shiozawa T; Wang TL; Fader AN; Shih IeM
    Gynecol Oncol; 2015 Nov; 139(2):338-44. PubMed ID: 26343160
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Dedifferentiated endometrial carcinomas with neuroendocrine features: a clinicopathologic, immunohistochemical, and molecular genetic study.
    Espinosa I; De Leo A; D'Angelo E; Rosa-Rosa JM; Corominas M; Gonzalez A; Palacios J; Prat J
    Hum Pathol; 2018 Feb; 72():100-106. PubMed ID: 29133142
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Expression of survivin, PTEN and p27 in normal, hyperplastic, and carcinomatous endometrium.
    Erkanli S; Kayaselcuk F; Kuscu E; Bagis T; Bolat F; Haberal A; Demirhan B
    Int J Gynecol Cancer; 2006; 16(3):1412-8. PubMed ID: 16803539
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Alteration of PTEN expression in endometrial carcinoma is associated with down-regulation of cyclin-dependent kinase inhibitor, p27.
    An HJ; Lee YH; Cho NH; Shim JY; Kim JY; Lee C; Kim SJ
    Histopathology; 2002 Nov; 41(5):437-45. PubMed ID: 12405911
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Expression of tumor suppressor gene product p14ARF in endometrioid adenocarcinoma of the uterine corpus.
    Watanabe J; Nishizaki R; Jobo T; Kamata Y; Hata H; Nishimura Y; Fujisawa T; Okayasu I; Kuramoto H
    Int J Gynecol Pathol; 2004 Jul; 23(3):234-40. PubMed ID: 15213599
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Two Distinct Tumorigenic Processes in Endometrial Endometrioid Adenocarcinoma.
    Sugiyama Y; Gotoh O; Fukui N; Tanaka N; Hasumi K; Takazawa Y; Noda T; Mori S
    Am J Pathol; 2020 Jan; 190(1):234-251. PubMed ID: 31733184
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Association of ovarian hyperthecosis with endometrial polyp, endometrial hyperplasia, and endometrioid adenocarcinoma in postmenopausal women: a clinicopathological study of 238 cases.
    Zhang C; Sung CJ; Quddus MR; Simon RA; Jazaerly T; Lawrence WD
    Hum Pathol; 2017 Jan; 59():120-124. PubMed ID: 27746268
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Loss of heterozygosity on 10q23.3 and mutation of the tumor suppressor gene PTEN in benign endometrial cyst of the ovary: possible sequence progression from benign endometrial cyst to endometrioid carcinoma and clear cell carcinoma of the ovary.
    Sato N; Tsunoda H; Nishida M; Morishita Y; Takimoto Y; Kubo T; Noguchi M
    Cancer Res; 2000 Dec; 60(24):7052-6. PubMed ID: 11156411
    [TBL] [Abstract][Full Text] [Related]  

  • 55. IMMUNOHISTOCHEMISTRY IN ENDOMETRIAL HYPERPLASIA AND ENDOMETRIAL ADENOCARCINOMA.
    Socolov D; Socolov R; Lupascu IA; Rugina V; Gabia O; Garauleanu DM; Carauleanu A
    Rev Med Chir Soc Med Nat Iasi; 2016; 120(2):355-62. PubMed ID: 27483717
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Theories of endometrial carcinogenesis: a multidisciplinary approach.
    Sherman ME
    Mod Pathol; 2000 Mar; 13(3):295-308. PubMed ID: 10757340
    [TBL] [Abstract][Full Text] [Related]  

  • 57. MITO END-3: efficacy of avelumab immunotherapy according to molecular profiling in first-line endometrial cancer therapy.
    Pignata S; Califano D; Lorusso D; Arenare L; Bartoletti M; De Giorgi U; Andreetta C; Pisano C; Scambia G; Lombardi D; Farolfi A; Cinieri S; Passarelli A; Salutari V; De Angelis C; Mignogna C; Priolo D; Capoluongo ED; Tamberi S; Scaglione GL; Arcangeli V; De Cecio R; Scognamiglio G; Greco F; Spina A; Turinetto M; Russo D; Carbone V; Casartelli C; Schettino C; Perrone F
    Ann Oncol; 2024 Jul; 35(7):667-676. PubMed ID: 38704093
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Utilization of unlabeled probes for the detection of fibroblast growth factor receptor 2 exons 7 and 12 mutations in endometrial carcinoma.
    Liu T; Willmore-Payne C; Wallander ML; Layfield LJ
    Appl Immunohistochem Mol Morphol; 2011 Jul; 19(4):341-6. PubMed ID: 21285871
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Immunohistochemical and genetic profiles of endometrioid endometrial carcinoma arising from atrophic endometrium.
    Geels YP; van der Putten LJ; van Tilborg AA; Lurkin I; Zwarthoff EC; Pijnenborg JM; van den Berg-van Erp SH; Snijders MP; Bulten J; Visscher DW; Dowdy SC; Massuger LF
    Gynecol Oncol; 2015 May; 137(2):245-51. PubMed ID: 25773202
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Development of metastatic endometrial endometrioid adenocarcinoma while on progestin therapy for endometrial hyperplasia.
    Rubatt JM; Slomovitz BM; Burke TW; Broaddus RR
    Gynecol Oncol; 2005 Nov; 99(2):472-6. PubMed ID: 16099019
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.